Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA network open"
DOI: 10.1001/jamanetworkopen.2022.53285
Abstract: Importance High-grade gliomas (HGGs) constitute the most common and aggressive primary brain tumor, with 5-year survival rates of 30.9% for grade 3 gliomas and 6.6% for grade 4 gliomas. The add-on efficacy of interferon alfa… read more here.
Keywords: grade gliomas; patients newly; newly diagnosed; alfa ... See more keywords
Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26644
Abstract: Patients with chronic kidney disease (CKD) develop anemia largely because of inappropriately low erythropoietin (EPO) production and insufficient iron available to erythroid precursors. In four phase 3, randomized, open‐label, clinical trials in dialysis‐dependent and non–dialysis‐dependent… read more here.
Keywords: anemia associated; chronic kidney; alfa; kidney disease ... See more keywords
Efanesoctocog Alfa versus Standard and Extended Half-Life Factor VIII Prophylaxis in Adolescent and Adult Patients with Haemophilia A without Inhibitors
Sign Up to like & getrecommendations! Published in 2024 at "Advances in Therapy"
DOI: 10.1007/s12325-024-03032-3
Abstract: In the Phase 3 XTEND-1 trial, (NCT04161495) efanesoctocog alfa prophylaxis provided superior bleed protection versus pre-study factor VIII (FVIII) replacement therapy in patients with severe haemophilia A. The aim of this study was to indirectly… read more here.
Keywords: efanesoctocog alfa; therapy; fviii replacement; shl ... See more keywords
Mobility and Quality of Life in Adults with Paediatric-Onset Hypophosphatasia Treated with Asfotase Alfa: Results from UK Managed Access Agreement
Sign Up to like & getrecommendations! Published in 2025 at "Advances in Therapy"
DOI: 10.1007/s12325-025-03168-w
Abstract: Hypophosphatasia (HPP) is a rare disease caused by deficient tissue–non-specific alkaline phosphatase (ALP) activity. Asfotase alfa is a tissue–non-specific ALP enzyme-replacement therapy which was reimbursed in the UK under a Managed Access Agreement (MAA). This… read more here.
Keywords: treatment; hypophosphatasia; mobility; alfa ... See more keywords
Efbemalenograstim Alfa, an Fc Fusion Protein, Long‑Acting Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, Open‑Label Trial
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Drug Investigation"
DOI: 10.1007/s40261-025-01479-y
Abstract: Neutropenia is the most severe hematologic toxicity of myelosuppressive chemotherapy. The objective of this study was to evaluate the safety and efficacy of efbemalenograstim alfa versus filgrastim for neutropenia support in patients with breast cancer… read more here.
Keywords: dose efbemalenograstim; efbemalenograstim alfa; chemotherapy; alfa ... See more keywords
SEBELIPASE ALFA IN CHILDREN AND ADULTS WITH LYSOSOMAL ACID LIPASE DEFICIENCY: FINAL RESULTS OF THE ARISE STUDY.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of hepatology"
DOI: 10.1016/j.jhep.2021.10.026
Abstract: BACKGROUND & AIMS Children and adults with lysosomal acid lipase deficiency (LAL-D) experience cirrhosis and dyslipidemia from lysosomal accumulation of cholesteryl esters and triglycerides. Sebelipase alfa enzyme replacement therapy is indicated for individuals with LAL-D.… read more here.
Keywords: open label; sebelipase alfa; lysosomal acid; alfa ... See more keywords
Comparison of efficacy between beractant and poractant alfa in respiratory distress syndrome among preterm infants (28–33+6 weeks gestational age) using the less invasive surfactant administration (LISA) technique: A randomized controlled trial
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Perinatology"
DOI: 10.1038/s41372-024-01962-y
Abstract: Exogenous surfactant therapy is vital in managing respiratory distress syndrome (RDS) in preterm infants, with less invasive surfactant administration (LISA) gaining popularity. This study aimed to assess the efficacy and short-term outcomes of LISA using… read more here.
Keywords: beractant poractant; preterm infants; efficacy; alfa ... See more keywords
The budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2022.2082200
Abstract: Abstract Aim Gaucher disease (GD) is a rare autosomal recessive condition. Type 1 GD (GD1) is the most prevalent form of GD in Western countries; enzyme replacement therapy (ERT) is a treatment option for patients… read more here.
Keywords: alfa; velaglucerase alfa; budget impact;
Preprint Highlight: ALIBY: ALFA nanobody-based toolkit for imaging and biochemistry in yeast.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular biology of the cell"
DOI: 10.1091/mbc.p22-10-1004
Abstract: Many commonly used protein epitope tags are optimized for one or a few biological applications. The recently developed ALFA tag performs well across a broad range of cell biological applications including localization, biochemical, and functional… read more here.
Keywords: highlight aliby; alfa nanobody; preprint highlight; alfa ... See more keywords
Novel Long-Acting Ropeginterferon Alfa-2b: Pharmacokinetics, Pharmacodynamics, and Safety in a Phase I Clinical Trial.
Sign Up to like & getrecommendations! Published in 2021 at "British journal of clinical pharmacology"
DOI: 10.1111/bcp.15176
Abstract: AIM Ropeginterferon alfa-2b is a novel, long-acting pegylated interferon alfa-2b. We aimed to evaluate its safety, pharmacokinetics (PK) and pharmacodynamics (PD). METHODS Thirty-six subjects received single subcutaneous injection of ropeginterferon alfa-2b at doses ranging 24-270… read more here.
Keywords: safety; pegylated ifn; ropeginterferon alfa; ifn alfa ... See more keywords
Comprehensive laboratory assessment of lonoctocog alfa versus octocog alfa in severe haemophilia A
Sign Up to like & getrecommendations! Published in 2024 at "Haemophilia"
DOI: 10.1111/hae.15089
Abstract: Lonoctocog alfa is a single‐chain factor VIII (FVIII) molecule with high binding affinity to von‐Willebrand‐factor. While it is well known that its plasma activity is underestimated by one‐stage clotting assays (OSCA), there is a lack… read more here.
Keywords: haemophilia comprehensive; lonoctocog alfa; laboratory assessment; comprehensive laboratory ... See more keywords